Drug companies are wary of President Donald Trump's proposed policies regarding lowering the cost of drug prices, which has led them to delay some European launches. Drug launches in EU markets fell by 35% in the 10 months since Trump's executive order, compared to the previous 10 months. This has led drug companies to pause bringing some medicines to European markets where health spending is lower. The uncertainty around U.S. pricing benchmarks and enforcement is causing uncertainty for companies and forcing them to disclose their financial projections. France's head of health authority, Lionel Collet, said drugmakers were increasingly deferring decisions on France's early-access pathway, which allows patients to receive some medicines before formal approval.